For help on how to get the results you want, see our search tips.
3 results
Categories
Human Remove Human filter
Medicine
Referrals Remove Referrals filter
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Medicine type
Exceptional circumstances Remove Exceptional circumstances filter
Additional monitoring Remove Additional monitoring filter
Referral PRAC recommendation
Suspension Remove Suspension filter
Risk minimisation measures Remove Risk minimisation measures filter
Referral decision making model
PRAC-CHMP-EC Remove PRAC-CHMP-EC filter
Referral safety status
Yes Remove Yes filter
-
List item
Referral: Janus kinase inhibitors (JAKi)
tofacitinib, abrocitinib, baricitinib, upadacitinib, filgotinib, associated names: Xeljanz, Cibinqo, Olumiant, Rinvoq, Jyseleca, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/01/2023, EC decision date: 10/03/2023, Last updated: 22/05/2023 -
List item
Referral: Picato
ingenol mebutate, associated names: Picato, Article 20 procedures
Status: European Commission final decision, opinion/position date: 30/04/2020, EC decision date: 06/07/2020, Last updated: 16/11/2020 -
List item
Referral: Lemtrada
alemtuzumab, associated names: Lemtrada, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 16/01/2020, Last updated: 04/02/2020